In last trading session, Perspective Therapeutics Inc (AMEX:CATX) saw 0.39 million shares changing hands with its beta currently measuring 1.11. Company’s recent per share price level of $2.59 trading at -$0.03 or -1.15% at ring of the bell on the day assigns it a market valuation of $175.05M. That closing price of CATX’s stock is at a discount of -635.52% from its 52-week high price of $19.05 and is indicating a premium of 10.42% from its 52-week low price of $2.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 900.80K if we extend that period to 3-months.
For Perspective Therapeutics Inc (CATX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.26 in the current quarter.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Upright in the red during last session for losing -1.15%, in the last five days CATX remained trading in the red while hitting it’s week-highest on Thursday, 03/13/25 when the stock touched $2.59 price level, adding 7.83% to its value on the day. Perspective Therapeutics Inc’s shares saw a change of -18.81% in year-to-date performance and have moved -0.77% in past 5-day. Perspective Therapeutics Inc (AMEX:CATX) showed a performance of -14.52% in past 30-days. Number of shares sold short was 5.91 million shares which calculate 9.16 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 21 to the stock, which implies a rise of 87.67% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -672.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of -672.2% for stock’s current value.
Perspective Therapeutics Inc (CATX) estimates and forecasts
This year revenue growth is estimated to rise 1.74% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 277.3k for the same. And 5 analysts are in estimates of company making revenue of 121.06k in the next quarter. Company posted -4.9M and 325k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.69% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.91% while estimates for its earnings growth in next 5 years are of 4.54%.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Insiders are in possession of 20.41% of company’s total shares while institution are holding 70.53 percent of that, with stock having share float percentage of 88.62%. Investors also watch the number of corporate investors in a company very closely, which is 70.53% institutions for Perspective Therapeutics Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Advisor Biotechnology Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.69 shares of worth $4.39 million or 2.51% of the total outstanding shares. The later fund manager was in possession of 1.64 shares on Dec 31, 2024 , making its stake of worth around $4.26 million in the company or a holder of 2.43% of company’s stock.
